HOME >> BIOLOGY >> NEWS
How alcohol use during pregnancy can lead to attention-deficit/hyperactivity disorder

  • Prenatal alcohol, cocaine and lead exposure can lead to attention deficit disorder and hyperactivity.
  • Spontaneous-activity levels of dopamine neurons help the brain focus attention.
  • Fetal alcohol exposure decreases the activity of dopamine neurons in the midbrain area, decreasing attention.
  • Stimulants like Ritalin can increase focus by restoring dopamine deficits.

The relationship between fetal alcohol exposure and brain function is as complex as the brain itself. Recently, however, a study funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) may have found a common linkage--spontaneous activity of dopamine neurons--between prenatal alcohol exposure and attention-deficit/hyperactivity disorder (ADHD).

Although a mere three or four pounds in weight, the brain is composed of billions of nerve cells called neurons. Neurons communicate with each other at places called synapses by way of chemical messengers called neurotransmitters. Neurons generate electrical events called "action potentials" which cause neurotransmitters to travel across synapses, either "exciting" or "inhibiting" the "postsynaptic" or receiving cell. At any given moment, neurons are sending and/or receiving thousands of these messages. Scientists believe there are 100 or so different neurotransmitter varieties in the brain. Each neurotransmitter plays some role in most behaviors, but each neurotransmitter is often identified with a key behavior. Dopamine, for example, is strongly associated with motor system function, pleasure/reward, mental illness, craving and attention.

"The number of dopamine neurons isn't necessarily important," said Roh-Yu Shen, Senior Scientist at the Research Institute on Addictions, State University of New York and lead author of the study published in the November issue of Alcoholism: Clinical & Experimental Research. "What's important is how many of them are active."

Researchers g
'"/>

Contact: Roh-Yu Shen, Ph.D.
shen@ria.org
716-887-2593
Alcoholism: Clinical & Experimental Research
13-Nov-1999


Page: 1 2 3

Related biology news :

1. A liking for sweets, combined with novelty seeking, may predict alcoholism
2. Genes can influence both alcohol consumption and dependence
3. Infant rats eagerly accept high concentrations of alcohol upon first exposure
4. Acamprosate: potential medication for treating alcoholism
5. Antioxidants during pregnancy may help prevent birth defects tied to alcohol
6. Drunken worms reveal a genetic basis of alcohol response
7. Gene linked to alcoholism
8. Moderate alcohol consumption increases plasma levels of a protective hormone
9. Researchers find no link between alcohol consumption during pregnancy and asthma during childhood
10. Nonalcoholic beverages may impart cardiovascular benefits without the negative effects of alcohol
11. Gene therapy reduces drinking in rats with genetic predisposition to alcoholism

Post Your Comments:
(Date:5/10/2015)... , May 11, 2015 Fingerprint ... sensors FPC1025 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... will be used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK for ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
(Date:5/20/2015)... 20, 2015 Veracyte, Inc . ... demonstrating the ability of the company,s molecular classifier ... other interstitial lung diseases (ILDs) using samples obtained ... to help thousands of patients avoid invasive, risky ... diagnosis – a frequent challenge for physicians and ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) has announced ... Outlook 2020 " report to their offering. ... medicine is expected to have huge marketing potential. Presently, ... the growth of deregulated organs. Several therapeutic molecules are ... form new tissue or sometimes organ transplant is required. ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
Cached News: